People with hair loss experience emotional struggles and body dysmorphia. Treatments like minoxidil, finasteride, and dutasteride are used, but results vary and can take time.
Fluridil was abandoned due to its weak effectiveness and low binding affinity to the androgen receptor, making it less competitive against DHT and testosterone. Users discuss its limited results compared to other treatments like pyrilutamide and RU58841.
Missing dutasteride for up to 50 days likely won't cause significant hair loss if used for over six months, as it provides long-lasting DHT suppression. Continuing other treatments like minoxidil and scalp care is recommended during any break.
The conversation discusses the less impressive results of Pyrilutamide (kx-836) in phase 3 compared to phase 2, with a suggestion that a longer study might show more significant results. One user reports personal success with Pyrilutamide, experiencing no further hair loss and gradual regrowth.
The conversation discusses using Sandalore for hair loss treatment, with a focus on finding the correct concentration for a topical lotion. The consensus is to start with a 0.1% concentration due to potential scalp irritation at higher levels.
A user is considering using melatonin for hair recovery on the side and neck area but is unsure about the best options in Europe and whether a dietary supplement form can be applied to the scalp. They found a product but are hesitant and seeking opinions on its use for alopecia.
The conversation humorously discusses George Clooney's hair and aging, suggesting he switch to dutasteride for his temples. It also mentions minoxidil and finasteride, debating the effects of hair dye and styling on his appearance.
Ashwagandha may cause hair thinning due to increased TSH levels, suggesting a link to hypothyroidism. Users are advised to consult a doctor for proper evaluation.
A user is trying Relora supplements to reduce stress-induced hair shedding. They are frustrated with ongoing hair loss and are open to trying new solutions.
The user has been on finasteride for over four years without noticeable results and recently added dutasteride and RU58841, but continues to experience hair loss. They are considering stopping all medications due to lack of effectiveness and side effects like extremely dry eyes from dutasteride.
Breezula (clascoterone) initially performed better than finasteride for hair loss but then effectiveness decreased almost back to baseline after 6 months, raising questions about its strength.
The user has been using finasteride, minoxidil, and Nizoral for 9 months with little progress in hair regrowth and is considering switching to dutasteride. They experience daily scalp pain and anxiety, and are exploring other treatments like Head & Shoulders and consulting a dermatologist.
Taking dutasteride with a meal containing fat may improve absorption, but consistency in routine is more important than timing. Minor variations in absorption won't significantly affect efficacy due to dutasteride's long half-life.
The user has been using finasteride and dutasteride for six months, experiencing a complete stop in hair shedding but minimal regrowth. They are considering adding RU58841 for potential regrowth, with advice suggesting patience as significant results often take 12-24 months.
Clascoterone is considered overhyped and not as effective as finasteride or dutasteride, but it may be useful as a supportive treatment in combination with other therapies. Users express skepticism about its effectiveness compared to clinical trials, with some suggesting it could be beneficial for those who cannot tolerate other treatments.
Breezula's phase 2 showed reduced efficacy after 6 months, but phase 3 had positive results, causing confusion about any changes made to the drug. There is frustration over the long timeline for hair loss treatments, with some users expressing more interest in other potential treatments like GT-20029.
There is no new information on pp405, with data collection expected to finish by the end of 2025. Users are discussing the timeline for data analysis and completion of Pelage Pharmaceuticals' phase 2 study.
Clascoterone 5% solution showed a 539% improvement in hair count compared to placebo, but the actual increase in hair growth is minimal. Users express skepticism about the effectiveness of hair loss treatments.
A woman experiencing hair loss for over three years was diagnosed with female pattern hair loss and later with telogen effluvium, leading to a temporary stop of spironolactone treatment. She questions the diagnosis and treatment as her hair continues to worsen despite being advised to wait it out.
The conversation humorously suggests that the hair loss industry, referred to as "Big Bald," deliberately delays a cure to profit from ongoing treatments like minoxidil, finasteride, and dutasteride. Participants debate whether a cure would be more profitable than current treatments, with some suggesting that the industry prefers continuous treatments for sustained profit.
The user has been using a combination of treatments including Dutasteride, Minoxidil, RU58841, ketoconazole shampoo, microneedling, and low-level laser therapy to address hair loss but continues to experience shedding and density loss. Despite high testosterone and iron levels, the user is frustrated with the lack of improvement and is considering adjusting treatment or exploring other options like a hair transplant.
Pelage plans to release phase 2 results and start phase 3 trials for PP405 in 2050, but skepticism remains due to past delays and unfulfilled promises. Users express frustration over the lack of progress in hair loss treatments, mentioning Minoxidil, finasteride, RU58841, CB-03-01, and Fluridil.
PP405 is a new hair loss treatment showing early promise with a 20% hair density increase, but skepticism exists due to past failures of similar treatments like Pyrilutamide, RU58841, and Bimatoprost. Users debate its potential effectiveness, with some hopeful due to Google's involvement, while others urge caution without more evidence.
Finasteride can cause sleep disturbances, but these often improve over time. Some users experience side effects like reduced libido and brain fog, while others see hair regrowth and manage side effects by adjusting dosage or switching to topical treatments.
Concerns about the legitimacy of pyrilutamide solutions from Farmacia Tristaina due to low prices and lack of testing. Users suggest using Jano testing for product verification.
The user has been using 1.25 mg of oral minoxidil and finasteride since September 2025 to address diffuse hair thinning, and is considering trying a new shampoo. Other users suggest increasing the minoxidil dose and trying dutasteride.
Clascoterone (Breezula) shows promising hair growth results, but skepticism remains due to past disappointments with new treatments. It may be a good alternative for those who can't tolerate finasteride or dutasteride, and can potentially be combined with them and minoxidil for better results.
The user experienced increased hair thinning after switching from finasteride and minoxidil to dutasteride, despite some users suggesting it might be a temporary shedding phase. The user is considering using RU58841 but is unsure about its safety.
The user feels hopeless about hair loss despite using finasteride, dutasteride, minoxidil, and RU58841, and having a hair transplant. They are advised to maintain consistency in treatment, consider increasing dutasteride dosage, and explore topical solutions for better results.